CDSCO panel gives nod to Cadila to manufacture, market cholecalciferol aqueous injection 

The drug is indicated for the treatment of Vit D3 deficiency

The Subject Expert Committee under the Central Drugs Standard Control Organisation (CDSCO) has given nod to manufacture and market Cadila Pharma’s cholecalciferol aqueous injection 6,00,000 IU indicated for the treatment of Vit D3 deficiency.

The drug maker proposed to manufacture and marketing permission for cholecalciferol aqueous injection 6,00,000 IU along with serum calcium level data of both the groups (Reference vs Test) after the drug administration in the PK/PD study before the committee.